The New Jersey-based capsule maker announced it is buying two specialized drug delivery firms this week, explaining that the aim is to enlarge its Dosage Form Solutions business.
“Xcelience provides us with specialized clinical trial manufacturing and supply capabilities for a broad range of solid dosage forms, as well as development and manufacturing for specialized products such as highly potent and controlled substance compounds,” Amit Patel, President of Capsugel Dosage Form Solutions, told this publication.
Powdersize, meanwhile, brings micronisation capabilities which will increase Capsugel’s formulation design services and offer customers an extended bioavailability enhancement technology platform, Patel added.
Capsugel will take on over 200 additional staff - around 170 from Xcelience and 40 from Powdersize – and the Xcelience and Powdersize will continue to operate from Tampa, Florida and Quakertown, Pennsylvania, respectively.
“The key capabilities that Capsugel is receiving in this transaction are complementary and additive to our existing offerings, and our focus is to increase growth opportunities for all three companies,” said Patel.
Investment banking firm Fairmount Partners advised Xcelience and Powdersize in the transactions with Capsugel. Financial terms were not revealed.
Since Capsugel launched its Dosage Form Solutions (DFS) business unit in February 2013, the firm has been growing both organically and through M&A activity.
First off the firm acquired Encap, and then in October 2013 the company completed the takeover of drug delivery firm Bend Research in a deal which Capsugel told us had been described by one of its pharma customers as “a marriage made in heaven.”
As to these leatest deals, “Capsugel will be an even stronger global leader in delivering high-quality, innovative dosage forms and solutions to our healthcare customers,” Patel told us, offering clients “technologies and specialized manufacturing capabilities to solve our customers’ most pressing product development challenges.”
These include bioavailability enhancement, modified release, biotherapeutic processing and formulation, and inhalation and abuse deterrent formulations.
The expanded set of capabilities will “make the company better positioned than ever before to leverage our science and engineering expertise… and partner with our customers through an alliance-based business model predicated on trust and collaboration” he added.